To hear about similar clinical trials, please enter your email below
Trial Title:
Oxycodone in Combination With Parathoracic Nerve Block is Used for Postoperative Analgesia in Lung Cancer
NCT ID:
NCT05742256
Condition:
Oxycodone
Conditions: Official terms:
Lung Neoplasms
Sufentanil
Oxycodone
Conditions: Keywords:
Oxycodone
Postoperative analgesia
lung cancer
thoracic paravertebral nerve block
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
Single (Participant)
Intervention:
Intervention type:
Drug
Intervention name:
Oxycodone 1mg/kg
Description:
Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9%
normal saline diluted to 100ml
Arm group label:
Test group 1(OCA group)
Other name:
Oxycodone
Intervention type:
Drug
Intervention name:
Oxycodone 1.5mg/kg
Description:
Test group 2 (OCB group): oxycodone 1.5mg/kg + flurbiprofen 50mg + ondansetron 16mg +
0.9% normal saline diluted to 100ml.
Arm group label:
Test group 2(OCB group)
Intervention type:
Drug
Intervention name:
Sufentanil
Description:
Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9%
normal saline diluted to 100ml.
Arm group label:
Control group(SF group)
Summary:
In this study, the effect of oxycodone combined with ultrasound-guided paravertebral
nerve block on the postoperative analgesic effect of thoracoscopic lung cancer was
investigated, and the effect and reasonable dose of oxycodone were explored, which
provided a reference for the clinical multimodal analgesia after thoracoscopic lung
cancer surgery.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Male or female, age > 60 years
2. Patients undergoing thoracoscopic lobectomy
3. ASA (American Academy of Anesthesiologists) Grades I-III
4. There were no obvious abnormalities in heart, liver, and kidney function
5. Sign the informed consent form for this clinical study
Exclusion Criteria:
1. History of oxycodone or sufentanil allergy
2. Renal or hepatic dysfunction
3. History of drug or alcohol abuse
4. Psychiatric disorders: schizophrenia, epilepsy, Parkinson's disease, myasthenia
gravis
5. Those who have difficulty communicating due to coma, severe dementia, speech
barrier, or those who cannot cooperate due to other diseases.
6. People with head trauma or other brain diseases -
Gender:
All
Minimum age:
60 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
March 1, 2023
Completion date:
December 31, 2024
Lead sponsor:
Agency:
Qianfoshan Hospital
Agency class:
Other
Source:
Qianfoshan Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05742256
